AMARIN CORP PLC\UK Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt
AMARIN CORP PLC\UK (AMRN) reported Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt of $22.90 million for the 9-month period ending 2012-09-30, per its 10-Q filed 2013-11-07.
Discontinued › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt · last filed 2013-11-07
- AMARIN CORP PLC\UK adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2012-09-30 was $0.00.
- AMARIN CORP PLC\UK adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2012-06-30 was $0.00.
- AMARIN CORP PLC\UK adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2012-03-31 was $22.90M.
- AMARIN CORP PLC\UK adjustments to additional paid in capital, equity component of convertible debt for fiscal 2009 was $5.33M.
| Period end | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 3 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 6 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 9 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 12 month |
|---|---|---|---|---|
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $0.00 derived: sum of 2 quarters · filed 2013-11-07 | $22.90M 10-Q · filed 2013-11-07 | |
| 2012-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08 | $22.90M 10-Q · filed 2013-08-08 | ||
| 2012-03-31 | $22.90M 10-Q · filed 2013-05-09 | |||
| 2009-12-31 | $5.33M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |